Prognostic value of PD-L1 in patients with metastatic renal cell carcinoma (mRCC) treated with antiangiogenic first line drugs (PROANG-SOGUG study)
PROANG-SOGUG | Clinical and Translational Oncology: 28 de Septiembre 2026
Adjuvant Nivolumab in High Risk Muscle Invasive Urothelial Carcinoma Real World Evidence from the PrInCIS NIADY Study of the Spanish Oncology Genitourinary Group (SOGUG)
First-Line Tivozanib in Favorable and Very Favorable Risk Metastatic Renal Cell Carcinoma: Real-World Evidence from the TIVOREAL-SOGUG Study
Distinct protein and metabolic profiles in patients with advanced clear-cell renal cell carcinoma treated with sunitinib: a study of the Spanish oncology genitourinary group
Tivozanib Monotherapy as First-Line Treatment in Intermediate-Risk Metastatic Renal Cell Carcinoma: TIVOREAL-SOGUG, a Spanish Real-World Experience
Validation of the IMDC Prognostic Model in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Tivozanib: TIVOREAL-SOGUG, A Spanish RealWorld Experience
Capacidad de distintos cuestionarios de cribado de fragilidad para predecir toxicidad severa, deterioro funcional y/o mortalidad al año en pacientes mayores con cáncer de próstata. Proyecto SOGUG-FRAGDOC
Correlación entre distintos cuestionarios de cribado de fragilidad en pacientes mayores con cáncer de próstata. Proyecto SOGUG-FRAGDOC
SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations
Defining Molecular Correlates of Response Using Spatial Transcriptomics in the SOGUG-AUREA Trial
Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group retrospective cohort study in Spain
SOGUG-RETROSPECTIVE INMUNOTERAPIA | DOI: BMC Cancer (2025) 25:1835
Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study
SOGUG-CABOMAYOR | DOI: Journal of Geriatric Oncology Volume 16, Issue 8 102340 November 2025
Therapeutic Alliances for Optimizing the Management of Patients with Prostate Cancer: SOGUG Multidisciplinary Expert Panel Recommendations
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
SOGUG-SPRWEC | DOI: Clinical Genitourinary Cancer, Volume 23, Issue 5, 102402 October 2025
SEOM–SOGUG clinical guideline for urothelial cancer (2025)
Split-Dose Cisplatin plus Atezolizumab for Patients with Urothelial Carcinoma Who Are Considered Ineligible for Full Doses of Cisplatin (SOGUG-AUREA)
SOGUG-AUREA | DOI: JCO Oncology Advances Published July 31, 2025, Volume 2, Number 1
Real‑world data on avelumab in first‑line maintenance therapy for advanced or metastatic urothelial carcinoma: the SOGUG‑AVELUMAB RWD study
SOGUG-AVELUMAB_RWD | DOI: Clinical and Translational Oncology (CTO)
SOGUG-NEODURVARIB: Treatment Efficacy and Molecular Dynamics of Neoadjuvant Durvalumab and Olaparib in Resectable Urothelial Bladder Cancer: The NEODURVARIB Trial
SOGUG-NEODURVARIB | DOI: Clin Cancer Res (2025) 31 (9): 1644–1656.
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial
Real-world evidence of nivolumab monotherapy in advanced renal cell carcinoma from a multicenter retrospective cohort study by the Spanish Genitourinary Oncology Group
REAL-WORD EVIDENCE OF NIVOLUMAB | DOI: BMC Cancer, Volume 25, article number 1835, (2025)
Bladder Preservation with Durvalumab plus Tremelimumab and Concurrent Radiotherapy in Patients with Localized Muscle-Invasive Bladder Cancer (IMMUNOPRESERVE): A Phase II Spanish Oncology GenitoUrinary Group Trial. 15 February, 2025.
EFFICACY AND SAFETY OF ATEZOLIZUMAB CONCURRENT WITH RADIOTHERAPY IN PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER: AN INTERIM ANALYSIS OF THE ATEZOBLADDERPRESERVE PHASE II TRIAL (SOGUG-2017-A-IEC(VEJ)-4)
"SOGUG-Vexillum: Phase II non randomized clinical trial of nivolumab / ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer"
SOGUG-AVELUMAB_RWD: COMPREHENSIVE ANALYSIS OF REAL-WORD DATA TO EVALUATE THE EFFECTIVENESS AND SAFETY OF AVELUMAB MAINTENANCE THERAPHY IN PATIENTS STAGE IV UROTHELIAL CARCINOMA CONDUCTED IN SPAIN
SOGUG-AVELUMAB | DOI: J Clin Oncol 42, 2024 (suppl 16; abstr e16561)
SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib and cetrelimab(CET) as neoadjuvant treatment in cisplatin-ineligible
SOGUG-NEOWIN: A Phase 2, open-label, multi-centre, multi-national interventional trial evaluating the efficacy and safety of erdafitinib (ERDA) monotherapy and erdafitinib and cetrelimab (CET) as neoadjuvant treatment in cisplatin-ineligible patients with muscle-invasive bladder cancer (MIBC) whose tumours express FGFR gene alterations
"Feasibility and Efficacy of Split-Dose Cisplatin with Atezolizumab for Cisplatin-Ineligible Urothelial Carcinoma (SOGUG-AUREA): Final Results"
"Effectiveness and safety of cabozantinib treatment in patients with advanced renal cell carcinoma (RCC) in Spanish and Portuguese real -world practice: Study SOGUG-SPRWEC"
SOGUG-Vexillum: Phase II non randomized clinical trial of nivolumab / ipilimumab maintenance following first-line chemotherapy in unresectable locally advanced or metastatic urothelial cancer
Nacional
Internacional
Nuestros patrocinadores
